SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?


To: Dr. John M. de Castro who wrote (1604)11/5/1998 8:19:00 PM
From: Steve Harmon  Respond to of 2742
 
John de C,

Where CIST is trading is not the problem here. Similiar manipulation occurs on the Nasdaq regular and small cap also.

Reverse splits are a way for inept management to cover up stupid financing deals...Look at SPTA and PRCT for recent reverse splits that tanked back to under a buck after the reverse occurred.

It is very obvious what has occurred in the last two years at Cistron...It is what i have dubbed over the years as BIOTECH CEO WELFARE.

A stock buyback which matches what the 2 officers left at Cistron would very easily support Cistron's stock at much higher levels. Not doing one ALLOWS our shares to trade at pathetic levels.

Steve




To: Dr. John M. de Castro who wrote (1604)11/5/1998 9:25:00 PM
From: Biomaven  Read Replies (2) | Respond to of 2742
 
John,

I wholeheartedly agree with you here - a reverse split that would get the stock out of the BB black hole would do a lot for the share price. Unfortunately, investors naively associate reverse splits with dying companies, because they are normally the only ones that do it. Usually reverse splits don't help because the company itself is in a decline which the reverse split doesn't help.

However the situation here is very different: this is a financially sound company trading way below book. I don't know what the chances of seeing any part of the $30 million from PM are; but I have to believe that PM would not shell out close on $2 million if they didn't believe there wasn't a fair shot at something useful.

I also agree that a stock buyback would make a lot of sense, as long as they keep enough assets and float to qualify for a Small Cap listing (which is harder than just maintaining a listing once you have one).

I'm actually considering buying some CIST at these levels, although the other thread veterans will probably think I'm crazy.

Peter



To: Dr. John M. de Castro who wrote (1604)11/24/1998 10:39:00 AM
From: Walter Morton  Respond to of 2742
 
CIST might be able to buy ENDG when the price goes down, but CIST cannot afford to buy BIOI. Maybe BIOI would be willing to merge?

biz.yahoo.com
biz.yahoo.com